CRISPR Therapeutics AGCRSPNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank64
3Y CAGR-15.6%
5Y CAGR+31.6%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-15.6%/yr
vs +36.5%/yr prior
5Y CAGR
+31.6%/yr
Recent deceleration
Acceleration
-52.1pp
Decelerating
Percentile
P64
Within normal range
vs 5Y Ago
4x
Strong expansion
Streak
3 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $338.87M | -13.4% |
| 2024 | $391.32M | -15.4% |
| 2023 | $462.29M | -17.9% |
| 2022 | $563.35M | +28.5% |
| 2021 | $438.38M | +411.2% |
| 2020 | $85.75M | +35.1% |
| 2019 | $63.49M | -60.8% |
| 2018 | $162.07M | +53.4% |
| 2017 | $105.64M | +44.1% |
| 2016 | $73.29M | - |